D.E. Shaw & Co
OLMA icon

D.E. Shaw & Co’s Olema Pharmaceuticals OLMA Stock Holding History

D.E. Shaw & Co’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$695K Buy
55,519
+16,289
+42% +$218K ﹤0.01% 3991
2026
Q1 		$585K Buy
39,230
+29,276
+294% +$652K ﹤0.01% 3772
2025
Q4 		$249K Buy
+9,954
New +$177K ﹤0.01% 4239
2025
Q1 		– Sell
-12,445
Closed -$72.6K – 4603
2024
Q4 		$72.6K Sell
12,445
-13,148
-51% -$131K ﹤0.01% 4189
2024
Q3 		$306K Buy
25,593
+4,534
+22% +$58K ﹤0.01% 3965
2024
Q2 		$228K Buy
21,059
+10,959
+109% +$119K ﹤0.01% 4027
2024
Q1 		$114K Sell
10,100
-1,789
-15% -$23.1K ﹤0.01% 3998
2023
Q4 		$167K Buy
+11,889
New +$160K ﹤0.01% 3911
2022
Q3 		– Sell
-154,081
Closed -$627K – 5427
2022
Q2 		$627K Sell
154,081
-58,289
-27% -$185K ﹤0.01% 3962
2022
Q1 		$905K Buy
212,370
+124,288
+141% +$685K ﹤0.01% 3996
2021
Q4 		$824K Buy
88,082
+20,656
+31% +$428K ﹤0.01% 4089
2021
Q3 		$1.86M Buy
67,426
+26,622
+65% +$719K ﹤0.01% 3101
2021
Q2 		$1.14M Sell
40,804
-75,725
-65% -$2.15M ﹤0.01% 3428
2021
Q1 		$3.87M Buy
+116,529
New +$4.99M ﹤0.01% 2052

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

D.E. Shaw & Co's OLMA Position: Q2 2026 in Review

D.E. Shaw & Co increased its Olema Pharmaceuticals (OLMA) stake by 42% in Q2 2026, buying an estimated $218K and bringing the position to 55,519 shares worth $695K. The position accounts for ﹤0.01% of the portfolio, ranked #3991.

D.E. Shaw & Co first reported a position in OLMA in Q1 2021 and has held it in 14 quarters since. The position peaked at $3.87M in Q1 2021. 185 funds tracked by Wall St. Rank hold OLMA as of Q2 2026.

  • D.E. Shaw & Co held 55,519 shares of Olema Pharmaceuticals worth $695K as of Q2 2026.
  • D.E. Shaw & Co bought 16,289 Olema Pharmaceuticals shares in Q2 2026, an estimated $218K.
  • Olema Pharmaceuticals made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #3991 holding.
  • D.E. Shaw & Co first reported a position in Olema Pharmaceuticals in Q1 2021 and has held it in 14 quarters since.
  • D.E. Shaw & Co's Olema Pharmaceuticals position peaked at $3.87M in Q1 2021.
  • 185 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.